Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Debt (2017 - 2025)

Ani Pharmaceuticals' Total Debt history spans 11 years, with the latest figure at $292.0 million for Q4 2025.

  • For Q4 2025, Total Debt fell 8.25% year-over-year to $292.0 million; the TTM value through Dec 2025 reached $292.0 million, down 8.25%, while the annual FY2025 figure was $292.0 million, 8.25% down from the prior year.
  • Total Debt for Q4 2025 was $292.0 million at Ani Pharmaceuticals, down from $297.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $318.3 million in Q4 2024 and bottomed at $183.4 million in Q1 2021.
  • The 5-year median for Total Debt is $287.1 million (2022), against an average of $281.9 million.
  • The largest annual shift saw Total Debt fell 8.27% in 2021 before it soared 56.55% in 2022.
  • A 5-year view of Total Debt shows it stood at $287.4 million in 2021, then dropped by 0.59% to $285.7 million in 2022, then changed by 0.0% to $285.7 million in 2023, then grew by 11.42% to $318.3 million in 2024, then dropped by 8.25% to $292.0 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Total Debt are $292.0 million (Q4 2025), $297.7 million (Q3 2025), and $314.7 million (Q2 2025).